Preimushchestva novoy fiksirovannoy kombinatsii saksagliptina i metformina modifitsirovannogo vysbozhdeniya v terapii sakharnogo diabeta 2 tipa


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The progressive nature of diabetes mellitus type 2 (DM2) and complex pathogenesis of the disease make it necessary to intensify treatment and widespread use of combination therapy in clinical practice to achieve glycemic targets. The use of fixed combinations in the treatment of DM2 may be associated with benefits of therapy as a convenient mode of administration of the drug, increased treatment compliance, and as a consequence - the improvement of metabolic and clinical outcomes of DM2. The emergence of a new fixed combination of saxagliptin and modified-release metformin, the drug Komboglyze Prolong, offers new treatment options for DM2 patients, providing more comfortable treatment regimen for the doctor and the patient. The advantage of this combination is associated not only with a single dose of the drug per day, but with complementary mechanisms of action of saxagliptin and modified-release metformin, effectiveness for all parameters of glycemic control, safety, including lower risk of hypoglycemia, the absence of adverse effects on body weight, and the absence of the risk of increasing the frequency of cardiovascular diseases.

Full Text

Restricted Access

About the authors

A. S Ametov

Email: endocrin@mtu-net.ru

References

  1. Guillausseau PJ. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab 2003;29:79-81.
  2. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008;14:71-5.
  3. Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800-805.
  4. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002;25:1015-21.
  5. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-41.
  6. Leichter SB. Making outpatient care of diabetes more efficient: analyzing noncompliance. Clin Diabetes 2005;23:187-90.
  7. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 2007;33:1014-29.
  8. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24.
  9. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-17.
  10. Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin 2012;8(6):969-77.
  11. Schernthaner G. Fixed-dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care. Diabet Med 2010;27(7):739-43.
  12. Инструкция по медицинскому применению лекарственного препарата Онглиза (таблетки, покрытые оболочкой, 2,5 и 5 мг). Регистрационное удостоверение ЛСР 08697/10 (изменение №1) от30.03.2012.
  13. Scirica BM, Bhatt DL, Braunwald E, et al.; the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013.
  14. Дедов И.И., Шестакова М.В. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 6-й выпуск. Москва, 2013.
  15. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of clinical endocrinologists/American college of endocrinology consensus panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
  16. Inzucchi SE, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55(6):1577-96.
  17. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-54.
  18. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003;63:1879-94.
  19. Setter SM, Iltz JL, Thams J, et al. Metformin hydrochloride in the treatment of Type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003;25:2991-3026.
  20. Consoli A, Gomis R, Halimi S, et al. Initiating oral glucose-lowering therapy with metformin in Type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 2004;30:509-16.
  21. Renda F, Mura P, Finco G, Ferrazin F, Pani L, Landoni G. Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review. Eur Rev Med Pharmacol Sci 2013;17(Suppl 1):45-9.
  22. Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. Diabetes Metab 2011;37(2):90-6.
  23. Инструкция по медицинскому применению лекарственного препарата Глюкофаж Лонг (таблетки, пролонгированного действия, 500 мг). Регистрационное удостоверение ЛСР 002098/10 (изменение №1) от 08.02.2013.
  24. Gusler G, Gorsline J, Levy G, et al. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol 2001;41:655-61.
  25. Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006;29(4):759-64.
  26. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther 2003;25(2):515-29.
  27. Scheen А. Saxagliptin plus metformin combination therapy Expert Rev Endocrinol Metab 2012;7(2):151-64.
  28. Mulherin AJ, Oh AH, Kim H, et al. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 2011;152(12):4610-19.
  29. Инструкция по медицинскому применению лекарственного препарата Комбоглиз Пролонг (таблетки с модифицированным высвобождением, покрытые оболочкой). Регистрационное удостоверение ЛП-002068 от 14.05.2013.
  30. Boulton DW, Smith CH, Li L, et al. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin Drug Investig 2011;31(9):619-30.
  31. Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab 2012;14(4):365-71.
  32. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled Type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-55.
  33. Rosenstock J, Gross JL, Aguilar-Salinas C, et al. Long-term 4-year safety of saxagliptin in drugnaive and metformin-treated patients with Type 2 diabetes. Diabet Med 2013.
  34. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with Type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11:611-22.
  35. Pfutzner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011;13:567-76.
  36. Goke B, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010;64(12):1619-31.
  37. Goke B, Gallwitz B, Eriksson JG, et al. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract 2013;67(4):307-16.
  38. Rao A, et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? Diabetes Care 2008;31:1672-78.
  39. Olsson J, et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000;43:558-60.
  40. Monami M, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006;22:477-82.
  41. Phung OJ, Schwartzman E, Allen RW, et al. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 2013 May 11. doi: 10.1111/ dme.12232.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies